UTMD Q2 Revenue Drops 14% on Lost Customers; Full-Year Guidance Cut to 10-13% Decline

summarizeSummary

UTMD's Q2 revenue fell 14% to $8.53M as lost customers hit hard; full-year guidance slashed to a 10-13% decline. New product sales are lagging, and litigation costs are up. Strong cash position provides a buffer.

check_boxKey Events · Earnings and Guidance · UTMD

• Q2 Revenue Miss

  Revenue of $8.53M, down 14.3% YoY, driven by $1.07M loss from two former largest customers.

• Full-Year Guidance Cut

  Management now projects 2026 sales decline of 10-13%, versus prior expectation of flat revenues, as new biopharma OEM sales ramp slower than expected.

• Litigation Costs Rising

  2026 litigation expenses now expected to be less than $1.6M, up from prior estimate of below 2025's $1.355M, due to higher expert witness and motion costs.

• Strong Balance Sheet

  Cash and investments of $87.5M, no debt, and minimal share repurchases of $206K in 1H 2026 provide financial stability.

auto_awesomeAnalysis · UTMD · Industrial Applications And Services

Utah Medical Products reported Q2 2026 revenue of $8.53 million, down 14.3% year-over-year, driven by the loss of its two largest customers which accounted for $1.07 million of the decline. New biopharma OEM sales, intended to offset these losses, reached only $211,000 in the first half—far slower than planned. Management now expects full-year 2026 sales to decline 10-13%, a sharp reversal from prior guidance of flat revenues. Litigation costs are also running higher than expected, now projected at less than $1.6 million for the year versus the prior estimate of below 2025's $1.355 million. The company maintains a fortress balance sheet with $87.5 million in cash and no debt, and share repurchases were minimal at $206,000 in the first half. The revenue miss and guidance cut signal deeper-than-expected customer concentration risk and a slower new product ramp, raising questions about the growth trajectory.